Darízy Flávia  Silva

Darízy Flávia Silva

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2019 in Skin Pharmacology and Physiology
Verified
Journal Article
Closed access
RARousilândia de Araújo
Rousilândia de Araújo
MLMyla Lôbo
Myla Lôbo
KTKelvis Trindade
Kelvis Trindade
DSDarízy Flávia Silva
Darízy Flávia Silva
NPNeila Pereira
Neila Pereira
Cutaneous aging is a complex and continuous biological process characterized by cellular and molecular alterations, with progressive reduction of the body’s capacity to maintain the homeostasis, senescence, and/or apoptosis of the dermal cells. Fibroblast growth factors (FGF) have elicited studies to evaluate their role of repair and remodeling of the dermis during the skin anti-aging process, since they are regulatory proteins that mediate important signaling pathways and act on cell regeneration and repair processes. FGF acts primarily through binding to tyrosine kinase receptors through the autophosphorylation of their residues, promoting the phosphorylation of serine, threonine, and tyrosine residues of specific target proteins such as Raf-1, MAPK/Erk kinase, and extracellular signal-regulated kinase-1, which are part of the cascade of MAP kinases (mitogen-activated protein kinase). Then, FGF initiate signaling cascades inside the cell, where each kinase activates the following by phosphorylation, resulting in alterations of cellular functions. In addition, the FGF has a relevant role in anti-aging therapy because it is related to collagen and elastin synthesis activation responsible for skin resistance and elasticity, characteristics that are diminished with skin aging. Thus, the present article aims to review several scientific studies that demonstrated the cell signaling involved with the action of FGF on skin aging.

21 February 2015 in DARU Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
TOTatiane Teixeira Oliveira
Tatiane Teixeira Oliveira
KCKeina Maciele Campos
Keina Maciele Campos
ACAna Tereza Cerqueira-Lima
Ana Tereza Cerqueira-Lima
TCTamires Cana Brasil Carneiro
Tamires Cana Brasil Carneiro
EVEudes da Silva Velozo
Eudes da Silva Velozo
CFCamila Figueiredo
Camila Figueiredo
Background: Asthma is an inflammatory condition characterized by airway hyperresponsiveness and chronic inflammation. The resolution of inflammation is an essential process to treat this condition. In this study we investigated the effect ofAllium cepaL. extract (AcE) and quercetin (Qt) on cytokine and on smooth muscle contractionin vitroand its therapeutic potential in a murine model of asthma.Methods: AcE was obtained by maceration ofAllium cepaL. and it was standardized in terms of quercetin concentration using high performance liquid chromatography (HPLC).In vitro, using AcE 10, 100 or 1000 μg/ml or Qt 3.5, 7.5, 15 μg/ml, we measured the concentration of cytokines in spleen cell culture supernatants, and the ability to relax tracheal smooth muscle from A/J mice.In vivo,Blomia tropicalis(BT)-sensitized A/J mice were treated with AcE 100, 1000 mg/kg or 30 mg/kg Qt. We measured cell influx in bronchoalveolar lavage (BAL), eosinophil peroxidase (EPO) in lungs, serum levels of Bt-specific IgE, cytokines levels in BAL, and lung histology.Results: We observed a reduction in the production of inflammatory cytokines, a relaxation of tracheal rings, and a reduction in total number of cells in BAL and EPO in lungs by treatment with AcE or Qt.Conclusion: AcE and Qt have potential as antiasthmatic drugs, as they possess both immunomodulatory and bronchodilatory properties.

1 April 2015 in Vascular Pharmacology
Verified
Journal Article
Closed access
BDBruna Priscilla Vasconcelos Dantas
Bruna Priscilla Vasconcelos Dantas
QAQuiara Lovatti Alves
Quiara Lovatti Alves
KAKívia Sales de Assis
Kívia Sales de Assis
TRThais PORTO RIBEIRO
Thais PORTO RIBEIRO
MAMônica Moura de Almeida
Mônica Moura de Almeida
DSDarízy Flávia Silva
Darízy Flávia Silva

26 February 2021 in Frontiers in Physiology
Verified
Journal Article
Open access
RMRaiana dos Anjos Moraes
Raiana dos Anjos Moraes
RWR. Clinton Webb
R. Clinton Webb
DSDarízy Flávia Silva
Darízy Flávia Silva
Transient receptor potential (TRP) superfamily consists of a diverse group of non-selective cation channels that has a wide tissue distribution and is involved in many physiological processes including sensory perception, secretion of hormones, vasoconstriction/vasorelaxation, and cell cycle modulation. In the blood vessels, TRP channels are present in endothelial cells, vascular smooth muscle cells, perivascular adipose tissue (PVAT) and perivascular sensory nerves, and these channels have been implicated in the regulation of vascular tone, vascular cell proliferation, vascular wall permeability and angiogenesis. Additionally, dysfunction of TRP channels is associated with cardiometabolic diseases, such as diabetes and obesity. Unfortunately, the prevalence of diabetes and obesity is rising worldwide, becoming an important public health problems. These conditions have been associated, highlighting that obesity is a risk factor for type 2 diabetes. As well, both cardiometabolic diseases have been linked to a common disorder, vascular dysfunction. In this review, we briefly consider general aspects of TRP channels, and we focus the attention on TRPC (canonical or classical), TRPV (vanilloid), TRPM (melastatin), and TRPML (mucolipin), which were shown to be involved in vascular alterations of diabetes and obesity or are potentially linked to vascular dysfunction. Therefore, elucidation of the functional and molecular mechanisms underlying the role of TRP channels in vascular dysfunction in diabetes and obesity is important for the prevention of vascular complications and end-organ damage, providing a further therapeutic target in the treatment of these metabolic diseases.

1 May 2018 in Biochemical Pharmacology
Verified
Journal Article
Closed access
SCSamuel Barbosa Camargo
Samuel Barbosa Camargo
LSLetícia Oliveira Simões
Letícia Oliveira Simões
CMCarla Fiama de Azevedo Medeiros
Carla Fiama de Azevedo Medeiros
AJAnderson de Melo Jesus
Anderson de Melo Jesus
JFJosmara Bartolomei Fregoneze
Josmara Bartolomei Fregoneze
DSDarízy Flávia Silva
Darízy Flávia Silva

8 August 2011 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
DSDarízy Flávia Silva
Darízy Flávia Silva
IAIslania G. A. Araújo
Islania G. A. Araújo
JAJosé G. F. Albuquerque
José G. F. Albuquerque
DPDayanne L. Porto
Dayanne L. Porto
KDKaty L. G. Dias
Katy L. G. Dias
IMIsac Almeida de Medeiros
Isac Almeida de Medeiros